Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emmaus Plans Modest Pricing In 4Q Rollout Of Sickle Cell Drug Endari

Executive Summary

With an eye on a patient population mainly covered by Medicare and Medicaid, Emmaus Life Sciences CEO Yutaka Niihara says the company wants to ensure its pharmaceutical grade L-glutamine product is accessible in the US.

Advertisement

Related Content

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More
GBT Picks Up Inclacumab From Roche's Bargain Bin
Global Blood Makes Case For Accelerated Approval Of Sickle Cell Drug Voxelotor
EMA Says Yes To First Sickle Cell Drug For PRIME
Unmet Need Can Trump Anything At US FDA Panels, Even An Ill-Prepared Sponsor
Sickle Cell Innovators Required: Emmaus' Pending Approval Highlights Rare Disease Void
Novartis Buys Selexys As Competitors Stumble In Sickle Cell

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel